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Abstract: A scalable, cost-efficient and simple synthetic pathway towards pot-
ential bivalent opioid/dopamine receptor ligands was developed and optimized. 
Three novel compounds that contain both opioid and dopamine pharmaco-
phores linked by the four methylene group chain were synthesized in 33, 35 
and 39 % overall yield after a four-step synthetic route starting from three 
commercially available N-aryl piperazines. The anilino piperidine precursor 
was easily prepared in three steps, as previously published, starting from 4-
piperidone. The synthesis presented in this paper could be of interest for het-
erocyclic and general organic chemistry. The newly designed compounds pos-
sessing two pharmacophores, opioid and D2/D3, are potentially useful pharma-
cological probes. Of particular interest would be the simultaneous binding to 
both opioid and D2/D3 receptors, and the resulting pharmacological responses 
may be useful for the further understanding of tolerance and dependence phen-
omena in opioid clinical use and/or abuse. 
Keywords: piperidine; piperazine; heterocycles; N-alkylation; analgesics; dopa-
minergic. 
INTRODUCTION 
4-Anilido-piperidines and N-aryl piperazines are pharmacologically impor-
tant moieties.1–6 Both of these pharmacophores are seen separately in numerous 
compounds possessing high pharmacological activities, many of which have 
found their way into clinical use. 4-Anilido-piperidines are best known for their 
analgesic activity since many of them act as μ-opioid receptor agonists in the 
central nervous system (CNS).1–4 Opioid analgesics are especially effective for 
the treatment of strong chronic and acute pain, when other standard analgesics, 
such as non-steroidal anti-inflammatory drugs (NSAIDs) are ineffective. There 
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are several highly potent opioid analgesics with a 4-anilido-piperidine core in 
clinical use, including fentanyl (Actiq® and Abstral®), sufentanil (Sufenta®), 
alfentanil (Alfenta®) and remifentanil (Ultiva®). The serious drawback when 
opioid usage is considered are side effects, among which the most important are 
tolerance and dependence due to prolonged treatment of chronic pain, with the 
most dangerous outcome being respiratory arrest due to CNS depression as a 
result of overdosing with opioids. The N-aryl piperazine scaffold is present in 
many compounds that are active towards the dopaminergic signalling system in 
the CNS, especially D2 and D3 receptor subtypes.5 Several antipsychotic drugs 
that are used in clinical practice for treatment of schizophrenia and bipolar dis-
orders are compounds that contain the piperazine moiety that act as D2 anta-
gonists, such as Geodon®, Clozaril®, or partial agonists, such as Abilify®. D2 
and D3 agonists however are clinically used for the treatment of Parkinson’s dis-
ease, for example Pronoran®.  
Recently it was discovered that activation of μ-opioid receptors influences 
the dopaminergic signal pathway, which in turn is believed to have a reinforcing 
effect on some psychoactive drugs. It was found that the drugs affecting the 
dopaminergic system can also influence the effect of opioid agonists on cognitive 
functions in animal models.7–14 These results are expected to be useful for 
further understanding of the tolerance and dependence phenomena in opioids 
addiction.  
In the past several decades, a large number of anilido piperidines have been 
prepared, particularly analogues with diverse substituents on the piperidine nit-
rogen. Interestingly, it seems that none of the substituents included a piperazine 
moiety.15,16 In view of the fact that many piperazines are significant D2/D3 
receptor pharmacophores, the aim of this study was to develop a synthetic route 
towards novel compounds as potential bivalent, opioid–dopaminergic ligands, 
having the general structure 1 (Fig. 1). Apparently, none of the bivalent, opioid–
dopaminergic ligands have hitherto been reported. 
 
Fig. 1. The general structure of bivalent 
ligand containing 4-anilido-piperidine 
and N-aryl piperazine moieties. 
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Designing multi-target drugs has become a growing area of medicinal chem-
istry in recent years. The aim of such drug design is to provide the structures that 
will be superior in efficacy and safety, relative to single target drugs. Introducing 
two pharmacophores, such 4-anilido-piperidine and N-aryl piperazine in one 
molecule could lead to interesting results in the pharmacological testing of such 
compounds, regarding their opioid and dopamine receptor activity. Therefore, the 
development of a synthetic pathway towards bivalent opioid/dopamine receptor 
ligands could be of interest to synthetic, heterocyclic and medicinal chemistry in 
general. 
EXPERIMENTAL 
General information 
Unless otherwise stated all solvents were freshly distilled under argon prior to use. All 
reagents purchased from a commercial vendor were used as supplied.  
1H- and 13C-NMR spectra were recorded on a Bruker Avance III spectrometer, at 500 
MHz for protons (1H) and at 126 MHz for carbons (13C). Chemical shifts are given in parts 
per million from tetramethylsilane (TMS) as the internal standard in CDCl3. The 2D NMR 
spectra (HSQC) were recorded at 500 MHz. Coupling constants (J) are reported in Hz. Unless 
otherwise stated, all spectra were recorded at 25 °C. High resolution mass spectra (HRMS) 
were obtained with a heated ESI (HESI)-Orbitrap spectrometer. Spectral and analytical data 
are given in Supplementary material to this paper. 
All reactions were monitored by thin layer chromatography (TLC). Flash and dry- 
-column flash chromatography17,18 were performed using silica gel (10−18 or 18–32 μm, 
ICN-Woelm). Melting points were obtained at a heating rate of 4 °C min-1 and are uncor-
rected. IR spectra were recorded using a Thermo Scientific Nicolet 6700 Fourier-transform 
spectrometer operated in the ATR mode.  
Structures of all new compounds were determined by methods of 1D, 2D NMR and IR 
spectroscopy. Structures of the three final compounds were additionally confirmed by high 
resolution mass spectrometry (HRMS). 
Syntheses 
General procedure for the synthesis of anilido-piperidines 8a and b. To a magnetically 
stirred solution of norfentanyl 4 (300 mg, 1.3 mmol) and K2CO3 (360 mg, 2.6 mmol) in 
MeCN (12 mL) was added bromochloro alkane (13 mmol). The mixture was allowed to stir at 
25 °C. The reaction was monitored by TLC with a mixture of CH2Cl2/MeOH = 95:5 as the 
eluent. After 24 h, Et2O was added, and the mixture was filtered, then concentrated by rotary 
evaporator. 10 % HBr (0.4 mL) was added, and mixture was extracted with 2×20 mL of 
n-hexane. Aqueous layer was then neutralised with 1.5 M solution of K2CO3 (pH ≈11) and 
extracted with 2×20 mL of CH2Cl2. The organic layers were combined and concentrated on a 
rotary evaporator. The crude product was purified by dry-column flash chromatography 
(SiO2; CH2Cl2/MeOH = 8:2 to 0:10). 
General procedure for the synthesis of aryl piperazino carboxamides 7a–c. To a magnet-
ically stirred solution of aryl piperazine hydrochloride 12a–c (3.5 mmol) in CH2Cl2 (10 mL), 
were added Et3N (425 mg, 4.2 mmol) and 4-chloro-butyrilchloride (740 mg, 5.25 mmol) at 0 
°C. The mixture was then allowed to stir. The reaction was monitored by TLC, with mixture 
of CH2Cl2/MeOH = 95:5 as the eluent. After 40 min stirring at 0 °C and an additional 20 min 
642 JEVTIĆ et al. 
at 25 °C, the reaction was complete. MeOH (10 mL) was then added, and the mixture was 
concentrated on a rotary evaporator. A solution of K2CO3 (1.5 M) was added (pH ≈11) and 
the mixture was extracted with 2×25 mL of CH2Cl2. The organic layers were collected and 
concentrated on a rotary evaporator. The crude product was used in the next step without 
further purification. 
General procedure for the synthesis of the aryl piperazino carboxamide-anilino-piper-
idine adducts (13a–c). To a magnetically stirred solution of anilino-piperidine 6 (300 mg, 1.7 
mmol) and K2CO3 (2 equiv.) in MeCN (12 mL), was added aryl piperazino carboxamide 7a–c 
(2.5 mmol). The mixture was stirred at 70 °C. The reaction was monitored by TLC, with mix-
ture of CH2Cl2/MeOH = 95:5 as the eluent. The reaction was completed after 8 h of reflux and 
additional stirring for 10 h at 25 °C. The mixture was then concentrated on a rotary evaporator 
and then 50 mL of CH2Cl2 was added and the mixture extracted with 2×25 mL of brine. The 
organic phase was concentrated on a rotary evaporator. The crude product was purified by 
dry-column flash chromatography (SiO2; CH2Cl2/MeOH = 1:0 to 95:5). 
General procedure for the synthesis of the aryl piperazino-anilino-piperidine adducts 
(5a–c). To a magnetically stirred suspension of aryl piperazino-anilino-piperidine adduct 13a–c 
(1.0 mmol) in dry THF (12 mL) was added 1M solution of BH3 in dry THF (34 mg, 2.5 
mmol) at 0 °C. Mixture was allowed to stir at 25 °C. After the spontaneous boiling stopped, 
the mixture was heated at 70 °C. The reaction was monitored by TLC with mixture of 
CH2Cl2/MeOH = 95:5 as the eluent. After 4 h of reflux, water (1 mL) was added dropwise, 
followed by the addition of 5.5 M HCl (2 mL) at 25 °C. Reflux was continued for an addi-
tional 4 h. Mixture was then concentrated on a rotary evaporator, 50 mL of CH2Cl2 was 
added, the layers were separated, and the organic phase was washed with 2×25 mL of brine. 
The organic phase was concentrated on a rotary evaporator. The crude product was purified 
by dry-column flash chromatography (SiO2; CH2Cl2/MeOH = 1:0 to 95:5). 
General procedure for the synthesis of aryl piperazino-anilido-piperidine adducts (1a–c). 
To a magnetically stirred solution of aryl piperazino-anilino-piperidine adduct 5a–c (0.6 
mmol) in CH2Cl2 (10 mL) was added Et3N (91 mg, 0.9 mmol) followed by the addition of 
propionyl chloride (EtCOCl, 166 mg, 1.8 mmol). The mixture was then allowed to stir at 25 
°C. The reaction was monitored by TLC with a mixture of CH2Cl2/MeOH = 95:5 as the 
eluent. After 3.5 h, MeOH (10 mL) was added, and the mixture was concentrated on a rotary 
evaporator. A solution of K2CO3 (1.5 M) was added (pH ≈11) and the mixture was extracted 
with 2×25 mL of CH2Cl2. The organic layers were collected, washed with 2×25 mL of brine, 
and concentrated on a rotary evaporator. The crude product was purified by dry-column flash 
chromatography (SiO2; CH2Cl2/MeOH = 1:0 to 95:5). 
RESULTS AND DISCUSSION 
The synthesis of bivalent ligands of the general structure 1 was initially 
attempted according to the retrosynthetic route A presented in Scheme 1. This 
approach was anticipated to include two simple alkylation steps of readily avail-
able piperazine and piperidine derivatives. 
While N-aryl piperazines are commercially available, the norfentanyl 4 was 
obtained according to a known literature procedure.19–22 For the starting material 
in the first alkylation step, norfentanyl 4 was selected as it was more readily 
available than the N-aryl piperazine 2. However, it was expected that both sec-
ondary amines would react similarly in this reaction. The alkylating agents were 
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linear α,ω-bromochloroalkanes having 3–6 methylene groups. Unexpectedly, 
1,4-bromochlorobutane and 1,5-bromochloropentane mainly gave the respective 
spiro-bicyclic quaternary ammonium salts 8a and b. Apparently, the entropic 
factor favoured the formation of five and six member rings, rather than the linear 
alkylation products. Since the spiro-bicyclic products were obtained under all 
attempted conditions, an alternative approach was sought. For further inves-
tigation of the synthetic route target compound of general formula 1, it was 
selected to have four methylene groups in the alkyl chain, since it could not be 
prepared by the previous method (Scheme 2) because of quaternary ammonium 
ion 8a formation. 
 
Scheme 1. Initial retrosynthetic route (Route A) and optimized retrosynthetic route (Route B) 
for the synthesis of 4-anilido-piperidine and N-aryl piperazine containing bivalent ligands. 
 
Scheme 2. Initial synthetic route towards bivalent ligands 1: alkylation of 4 with alkylating 
agents of different chain lengths. 
According to the retrosynthetic route B, replacing the two successive alkyl-
ation steps of the previous synthetic route with acylation and alkylation steps 
seemed to be a promising alternative for connecting the two pharmacophores as 
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no quaternisation is possible with an amide nitrogen. Indeed, this approach gave 
the desired ligands of general structure 1 (Scheme 3).  
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Scheme 3. Synthesis of 4-anilido-piperidine/N-aryl piperazine adducts 1a–c.  
As a synthon for a four methylene linker, 4-chlorobutyryl chloride was 
selected.23 Acylation of N-aryl piperazine hydrochloride 12a–c with 4-chloro-
butyryl chloride under standard acylation conditions24 successfully provided 
carboxamides 7a–c in almost quantitative yields (Scheme 3B). The required 
anilinopiperidine 6, was prepared according to Scheme 3A using a known pro-
tocol.25,26 Subsequent alkylation of 6 with carboxamides 7a–c provided inter-
mediates 13a–c in moderate yields (45–55 %). The reaction was slow, requiring 
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refluxing acetonitrile for several hours. Higher temperatures and longer reaction 
times were necessary for completion of the alkylation reaction, due to the relat-
ively low alkylation reactivity of alkyl chlorides compared to other alkylating 
reagents. A significant amount of side product 14a–c, which originated from 
alkylation of the aniline nitrogen, was detected in all three examples, while no 
quarterisation was observed. The aniline nitrogen is less nucleophilic than that of 
alkyl amines, however not sufficiently to afford chemoselective alkylation of just 
the secondary amino group in 6. Since there is no efficient way to selectively 
protect the aniline nitrogen in the presence of other amino groups, the moderate 
yields of the desired alkylation products 13a–c made this step the least effective 
in this reaction route. The structure of the dialkylated side product was confirmed 
in the case of 14b as a representative, and the spectra are presented in the Sup-
plementary material. 
Clean and complete reduction of the amide bond with borane afforded 5a–c 
in high yields. The final products 1a–c were obtained by propionylation of the 
aniline nitrogen and isolated in high yields, after purification and in overall yields 
of nearly 35 % starting from 12 (Scheme 3B and C). Compounds 1a–c may have 
significant potential in pharmacological testing and docking studies as novel 
bivalent ligands for opioid and dopamine D2/D3 receptors. Synthesis of ana-
logues with different chain lengths as well as their pharmacological testing and 
theoretical modelling, is part of ongoing research. 
CONCLUSIONS 
Three novel compounds that contain both opioid and D2/D3 receptors phar-
macophores connected by four methylene group linkers were synthesized via a 
scalable, cost-efficient and simple synthetic pathway. Starting from three differ-
ent N-aryl piperazines 12a–c and anilino-piperidine 6, the final products 1a–c 
were obtained in nearly 35 % overall yield after four steps employing two acyl-
ation as well as alkylation and reduction steps. The actual pharmacological act-
ivity of the synthesized bivalent ligands cannot be predicted. However, there is a 
significant possibility that opioid and/or dopamine receptor activity will be rev-
ealed in various pharmacological tests. Potentially, these results may help adv-
ance the understanding of the interaction between dopaminergic and opioid sig-
nal pathways as well as related phenomena. Therefore, the development of the 
synthetic pathway towards bivalent opioid/dopamine receptor ligands could be of 
interest to synthetic, heterocyclic and medicinal chemistry in general.  
SUPPLEMENTARY MATERIAL 
Spectral and analytical data of the synthesized compounds are available electronically 
from http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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И З В О Д  
СИНТЕТИЧКИ ПУТ ЗА СИНТЕЗУ ПОТЕНЦИЈАЛНИХ, БИВАЛЕНТНИХ ЛИГАНАДА 
КОЈИ ПОСЕДУЈУ ОПИОИДНУ И ДОПАМИН Д2/Д3 ФАРМАКОФОРУ 
ИВАНА И. ЈЕВТИЋ1, ЈЕЛЕНА З. ПЕЊИШЕВИЋ1, МИЛОВАН Д. ИВАНОВИЋ2 и СЛАЂАНА В. КОСТИЋ-РАЈАЧИЋ1 
1ИХТМ – Центар за хемију, Универзитет у Београду, Његошева 12, 11000 Београд и 2Хемијски 
факултет, Универзитет у Београду, Студентски трг 12–16, 11000 Београд 
Три нова једињења, која садрже опиоидну и допаминску фармакофору, спојене 
преко четири метиленске групе, синтетисанa су у четири фазе у укупном приносу од 
приближно 35 %, полазећи од три комерцијално доступна N-арилпиперазина. Анилино-
пиперидински прекурсор је добијен у три једноставне реакционе фазе, полазећи од 
4-пиперидона, према познатој литературној методи. Синтеза приказана у овом раду 
може бити од значаја за хетероцикличну и органску хемију у целини. Новосинтетисана 
једињења која поседују две фармакофоре, опиоидну и Д2/Д3, су потенцијално корисни 
супстрати за фармаколошка испитивања. Од посебног интереса може бити истовремено 
везивање за опиоидне и Д2/Д3 рецепторе, а резултујући фармаколошки одговор био би 
користан у даљем разумевању толеранције и зависности, као феномена везаних за кли-
ничку употребу и/или злоупотребу опијата. 
(Примљено 2. октобра, ревидирано 5 новембра, прихваћено 29. новембра 2018) 
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